Global specialist in serving science enabling customers to make the world healthier, cleaner, and safer through laboratory equipment and services.
Profile & Fundamentals
Thermo Fisher Scientific: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Thermo Fisher Scientific Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Company profile record
Thermo Fisher Scientific Inc
Common Stock · Health Care · Life Sciences Tools & Services
Company
- Company / asset
- Thermo Fisher Scientific Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- HQ
- 🇺🇸 United States
- Head office
- 168 Third Avenue, Waltham, MA, United States, 02451
Leadership & scale
- Chief executive
- Mr. Marc N. Casper
- CEO year born
- 1968
- Full-time employees
- 125K
- Fiscal year end
- December
- IPO date
- 1978-01-13
Fundamentals snapshot
- Market Cap
- USD 243.6B
- P/E
- 34.9x
- Revenue (Q2 26)
- USD 12.0B
- Profit (Q2 26)
- USD 1.7B
- Dividend Yield
- 0.2%
- Revenue (FY 25)
- USD 44.6B
- Shares in public float
- 368.8M
- Insider ownership
- 0.13%
Reporting & identifiers
- Symbol
- TMO.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US8835561023
- Asset ID
- equity_b5649eae-cacd-5a55-b622-d2acb17d1247
Ownership
Shares Outstanding
Latest: 371.0M | Max: 405.0M | Min: 371.0M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
99.41%
368.8M latest reported shares
Insider Ownership
0.13%
Latest reported insider stake
Short Float
0.01%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 405,000,000 |
| 2018-01-01 | 405,000,000 |
| 2019-01-01 | 402,000,000 |
| 2020-01-01 | 400,000,000 |
| 2021-01-01 | 398,000,000 |
| 2022-01-01 | 393,000,000 |
| 2023-01-01 | 388,000,000 |
| 2024-01-01 | 383,000,000 |
| 2025-01-01 | 377,000,000 |
| 2026-01-01 | 371,000,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 30,427,192 | 8.23% | 2026-03-31 |
| Vanguard Capital Management, LLC | 24,280,816 | 6.57% | 2026-03-31 |
| State Street Corp | 16,731,668 | 4.53% | 2026-03-31 |
| CI Private Wealth LLC | 16,191,744 | 4.38% | 2026-06-30 |
| Vanguard MStar Total Stk Mkt Idx Invest | 11,810,592 | 3.19% | 2026-08-31 |
| Morgan Stanley - Brokerage Accounts | 10,863,528 | 2.94% | 2026-03-31 |
| FMR Inc | 10,776,436 | 2.91% | 2026-03-31 |
| Vanguard 500 Index Investor | 9,871,362 | 2.67% | 2026-08-31 |
| Geode Capital Management, LLC | 8,407,891 | 2.27% | 2026-03-31 |
| Franklin Templeton Inc | 6,813,031 | 1.84% | 2026-03-31 |
| JPMorgan Chase & Co | 6,795,482 | 1.84% | 2026-03-31 |
| T. Rowe Price Associates, Inc. | 6,315,471 | 1.71% | 2026-03-31 |
| Capital World Investors | 6,195,370 | 1.68% | 2026-06-30 |
| Vanguard Portfolio Management, LLC | 6,163,370 | 1.67% | 2026-03-31 |
| Bank of America Corp | 5,533,403 | 1.5% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The latest financial results confirm a clear operational recovery as customer inventory destocking concludes. Second-quarter revenue rose to approximately twelve billion dollars, supported by solid five percent organic growth across commercial biopharma workflows. This performance proves that core laboratory ordering patterns have stabilized into predictable expansion. Underlying earnings quality is supported by robust trailing free cash flow exceeding seven billion dollars. While recurring sales of everyday consumables provide defensive stability, headline net income remains separated from adjusted figures due to significant acquisition-related amortization. Sustainable earnings growth now relies on steady volume expansion rather than post-pandemic surges.
The latest financial results confirm a clear operational recovery as customer inventory destocking concludes. Second-quarter revenue rose to approximately twelve billion dollars, supported by solid five percent organic growth across commercial biopharma workflows. This performance proves that core laboratory ordering patterns have stabilized into predictable expansion. Underlying earnings quality is supported by robust trailing free cash flow exceeding seven billion dollars. While recurring sales of everyday consumables provide defensive stability, headline net income remains separated from adjusted figures due to significant acquisition-related amortization. Sustainable earnings growth now relies on steady volume expansion rather than post-pandemic surges.
Revenue, Net Income, and Free Cash Flow
Latest: USD 44.6B | Max: USD 44.9B | Min: USD 2.0B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 33x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability metrics are steadily improving from post-pandemic lows, with adjusted operating margins recovering toward twenty-three percent. Favorable sales mix toward proprietary single-use consumables and specialized mass spectrometry platforms provides healthy operational leverage across global manufacturing plants. Efficiency programs systematically eliminate overhead and counter persistent wage inflation. However, consolidated gross margins remain well below pandemic peaks due to the expansion of lower-margin clinical services and competitive pricing in routine laboratory supplies, indicating that future margin expansion will require disciplined operational execution.
Profitability metrics are steadily improving from post-pandemic lows, with adjusted operating margins recovering toward twenty-three percent. Favorable sales mix toward proprietary single-use consumables and specialized mass spectrometry platforms provides healthy operational leverage across global manufacturing plants. Efficiency programs systematically eliminate overhead and counter persistent wage inflation. However, consolidated gross margins remain well below pandemic peaks due to the expansion of lower-margin clinical services and competitive pricing in routine laboratory supplies, indicating that future margin expansion will require disciplined operational execution.
Profitability Margins
Latest: 40.9% | Max: 50.1% | Min: 10.6%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
40.9%
Gross profit / revenue
Operating Margin
18.2%
Operating income / revenue
Net Margin
15.1%
Net income / revenue
FCF Margin
14.1%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 18,274,100,000 | 2,021,800,000 | 2,711,900,000 |
| 2017-12-31 | 20,918,000,000 | 2,225,000,000 | 3,497,000,000 |
| 2018-12-31 | 24,358,000,000 | 2,938,000,000 | 3,785,000,000 |
| 2019-12-31 | 25,542,000,000 | 3,696,000,000 | 4,047,000,000 |
| 2020-12-31 | 32,218,000,000 | 6,375,000,000 | 6,815,000,000 |
| 2021-12-31 | 39,211,000,000 | 7,725,000,000 | 7,020,000,000 |
| 2022-12-31 | 44,915,000,000 | 6,950,000,000 | 6,911,000,000 |
| 2023-12-31 | 42,857,000,000 | 5,995,000,000 | 6,927,000,000 |
| 2024-12-31 | 42,879,000,000 | 6,335,000,000 | 7,267,000,000 |
| 2025-12-31 | 44,557,000,000 | 6,737,000,000 | 6,293,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 32.53 | Trailing four quarters |
| 2024-12-31 | 31.45 | Trailing four quarters |
| 2023-12-31 | 34.35 | Trailing four quarters |
| 2022-12-31 | 31.14 | Annual net income |
| 2021-12-31 | 34.38 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 46.96 | 15.64 | 11.06 | 14.84 |
| 2017-12-31 | 46.27 | 15.62 | 10.64 | 16.72 |
| 2018-12-31 | 45.11 | 15.9 | 12.06 | 15.54 |
| 2019-12-31 | 44.41 | 16.67 | 14.47 | 15.84 |
| 2020-12-31 | 49.75 | 24.51 | 19.79 | 21.15 |
| 2021-12-31 | 50.07 | 26.31 | 19.7 | 17.9 |
| 2022-12-31 | 42.33 | 18.98 | 15.47 | 15.39 |
| 2023-12-31 | 40.98 | 16 | 13.99 | 16.16 |
| 2024-12-31 | 41.34 | 17.87 | 14.77 | 16.95 |
| 2025-12-31 | 40.93 | 18.2 | 15.12 | 14.12 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.